Clinical Trial Update: Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. [Phase 2]

View source ↗

Summary

A Phase 2 study of INC424 in regularly transfused patients with thalassemia major has completed, with results posted in 2017 evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia Major

Drugs mentioned

• INC424 (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thalassemia Major | Phase 2 | Status: COMPLETED | Results posted: 2017-06-15